Aole AI sphygmomanometer opens a new chapter in smart medical care

For hypertensive patients, there are three major cognitive blind spots in daily management: nearly 68% of patients believe that “asymptomatic withdrawal can be stopped”, 42% of the population fall into the misunderstanding of “only testing but not intervention”, and as many as 75% of drug users have never verified whether the blood pressure is up to standard. Behind these data, the industry pain points of traditional sphygmomanometer with single function, isolated data, and lack of professional guidance are reflected. The Aole R & D team spent three years working on the problem, deeply integrating the two-way oscilloscope method with the fourth-generation intelligent algorithm, so that the measurement accuracy can reach the 3mmHg medical device standard. At the same time, relying on the natural language processing ability of the iFLYTEK Mars model, it has created the first intelligent end point with healthy dialogue function. At seven o’clock in the morning, Auntie Wang, who lives in H